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Background. The receptor for advanced glycation end products (RAGE) is an inflammation-perpetuating receptor, and soluble
RAGE (sRAGE) is a marker of cellular RAGE expression. This study investigated whether raised plasma levels prior to surgery of
sRAGE or S100A8/A9 (a RAGE ligand) were associated with longer duration of hospital care in patients undergoing cardiac surgery
necessitating cardiopulmonary bypass.Methods. Patients (𝑛 = 130) undergoing elective cardiac surgerywere enrolled prospectively.
Plasma sRAGE and S100A8/A9 concentrations were measured before and 2 h after surgery. Results. Preoperative plasma sRAGE
increased significantly (𝑃 < 0.0001) from 1.06 ng/mL (IQR, 0.72–1.76) to 1.93 ng/mL (IQR, 1.14–2.63) 2 h postoperatively. Plasma
S100A8/9 was also significantly (𝑃 < 0.0001) higher 2 h postoperatively (2.37𝜇g/mL, IQR, 1.81–3.05) compared to pre-operative
levels (0.41 𝜇g/mL, IQR, 0.2–0.65). Preoperative sRAGE, but not S100A8/A9, was positively and significantly correlated with
duration of critical illness (𝑟 = 0.3, 𝑃 = 0.0007) and length of hospital stay (LOS; 𝑟 = 0.31, 𝑃 < 0.0005). Multivariate binary
logistic regression showed preoperative sRAGE to be, statistically, an independent predictor of greater than median duration of
critical illness (odds ratio 16.6, 𝑃 = 0.014) and to be, statistically, the strongest independent predictor of hospital LOS. Conclusion.
Higher preoperative plasma sRAGE levels were associated with prolonged duration of care in adults undergoing cardiac surgery
requiring cardiopulmonary bypass.
1. Introduction
First described as a receptor (R) for advanced glycation end
products (AGEs), RAGE is an immunoglobulin-like pattern
recognition receptor constitutively expressed at low levels
in all cells and at high levels in the lung [1, 2]. RAGE
also interacts with a range of damage-associated molecular
pattern molecules including the S100 proteins. S100A8/A9 is
a heterodimeric S100 protein released from leukocytes during
inflammation [3], and plasma, leukocyte, or bronchoalveolar
lavage levels correlate with disease activity in patients with
septic shock [4–6] or acute respiratory distress syndrome
(ARDS) [7].
RAGE is considered to be an inflammation-perpetuating
receptor because receptor activation leads to further RAGE
expression and sustained de novo synthesis of the inflamma-
tory transcription factor NF-𝜅B. Higher preoperative levels
of plasma sRAGE could be associated with a worse outcome
following surgery [8]. A “two-hit” model describes the role
of RAGE in inflammation which hypothesizes that chronic
conditions such as renal failure or diabetes and increasing age
per se [9], some of the preoperative risks factors for cardiac
surgery, represent a first inflammatory “hit,” leading to
widespread upregulation of RAGE expression [1]. A second,
superimposed acute inflammatory insult, such as cardiac
surgery necessitating (sn) cardiopulmonary bypass (CPB) or
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other conditions associated with hyperglycaemia, ischaemic
stress, and release of inflammatory mediators, leads to a
further increase of RAGE ligands [1].
A soluble form of RAGE (sRAGE) also exists and consists
of both shed membrane-bound RAGE ectodomain and
released endogenous secretory (es) RAGE [10]. Shed and
esRAGE are ligand-binding, have no signal transduction
capacity, and are often detected in plasma as a single entity
without distinction. Soluble RAGE is likely to act as a
decoy molecule to bind excess RAGE ligand and increased
levels could be considered protective [11]. However, it is also
possible that the production of sRAGE is an attempt by cells
to reduce cell surface receptor expression and to limit cellular
activation, in which sRAGE levels can reflect the extent of
cellular RAGE expression and activation. Whether levels of
sRAGE are associated with better or worse outcome might,
in part, reflect these two roles.
A number of studies have investigated associations
between plasma levels of sRAGE levels and outcome in
a number of critical illnesses [1, 12, 13]. An association
between adverse outcome and high plasma sRAGE levels
has been extensively studied in patients with ARDS [14–
17]. Plasma sRAGE levels are also raised in patients with
acute pancreatitis, with the highest levels in those with severe
organ failure [18]. In patients with sepsis [19] and pneumonia
[20], the highest levels were detected in nonsurvivors; and in
trauma victims, levels were correlated with the development
of acute renal failure [21]. In children undergoing cardiac
surgery, sRAGE levels increased and correlated with outcome
[22], and in adults, levels were raised postoperatively, but
associations with outcome were not reported [23]. However,
whether raised levels of sRAGE prior to a second inflamma-
tory insult such as snCPB result in poorer outcome has not
been investigated.
In order to test the hypothesis that RAGE axis activity
might be a prognostic biomarker, we measured sRAGE and
the sRAGE ligand, S100A8/A9, in the plasma of patients
undergoing complex or high risk snCPB, and we investigated
associations with clinical characteristics, operative values,
and outcome variables.
2. Methods
2.1. Patient Population and Sample Collection. Samples and
clinical datawere collected, prospectively, frompatients at the
Royal Brompton Hospital, London, UK (from 2007 to 2010),
who were undergoing cardiac snCPB. Patients preferentially
recruited were those requiring complex surgery (i.e., valve
replacement surgery and coronary artery bypass grafting or
more than one heart valve replaced/repaired) or, alternatively,
those deemed high risk (i.e., additive EuroSCORE ≥ 6 [24]).
These criteria were used to select patients with a greater
likelihood of elevated preoperative sRAGE, a prerequisite
for our hypothesis. The only exclusion criterion was lack
of informed consent. Blood was collected via indwelling
cannulae and if not for immediate analysis, it was processed
and plasma samples stored at −80∘C. Plasma samples were
collected immediately prior to and 2 h following snCPB
(interleukin-8 (IL-8), sRAGE, and S100A8/A9) or on the first
postoperative day (C-reactive protein (CRP)).
2.2. sRAGE and S100A8/A9 Assays. Commercially available
sandwich enzyme-linked immunosorbent assay (ELISA) kits
were used to measure sRAGE (R&D Systems, Oxford, UK)
and S100A8/9 (NovaTec Immundiagnostica GmbH, Ger-
many). sRAGE was measured in 129 samples due to loss of
one sample.
2.3. Clinical Data. Preoperative characteristics, age, gender,
bodymass index (BMI), creatinine, and additive EuroSCORE
were recorded. Operative and postoperative variables were
obtained following interrogation of an automated clinical
data collection system. In patients for whom a sufficient
sample was available, CRP (𝑛 = 106) and IL-8 (𝑛 = 122) were
measured as markers indicative of systemic inflammation
after snCPB using the N high-sensitivity CRP monoassay
with the BN ProsPec Nephelometer (Dade Behring, Deer-
field, Illinois) and a bead array assay (xMAP, Luminex, Texas,
USA), respectively. CRP was selected as it is one of the most
widely measured markers of inflammation; and IL-8 was
selected, because extensive literature supports an association
between this proinflammatory cytokine and adverse postop-
erative sequelae. Together, raised levels of these biomarkers
are indicative of a second inflammatory “hit” after-surgery.
The measure of oxygenation employed was PaO
2
: FiO
2
ratio (PFR). The first value recorded on return from theatre
to the intensive care unit (ICU) was used as a measure of
pulmonary organ dysfunction or respiratory failure. Dura-
tion of mechanical ventilation and incidence of acute lung
injury were recorded. Indices of clinical outcome included
ICU, hospital lengths of stay (LOS), and mortality. ICU
LOS was employed as a composite index reflecting the
degree of physiological derangement and the requirements
for supportive care. To obviate the influence of nonclinical
considerations such as “step-down” bed availability, elec-
tronic databases of patient physiological parameters were
analysed, and the duration that patients required advanced
therapies and monitoring was determined, as recommended
previously [25]. “Level 3 care” duration is one such calculated
variable; derived from the UK Critical Care Minimum Data
Set (CCMDS), it is defined as the time in hours that a patient
requires advanced therapies and monitoring at a level that
would be usually thought of as “intensive care” [26].
The study protocol was approved by the hospital research
ethics committee, and informed consent was obtained from
all patients. Reporting of the study conforms to STROBE and
the broader EQUATOR guidelines [27].
2.4. Statistics. Statistical analyses were performed to establish
associations between plasma biomarkers and clinical indices.
Nonparametric datawere expressed asmedian and interquar-
tile range (IQR) and compared using Wilcoxon matched-
pairs test with Dunn’s correction for 2 paired groups and
Friedman’s test for 3 paired groups. Parametric data were
expressed as mean ± standard error of the mean (SEM)
and compared using a paired Student’s 𝑡-test. Correlations
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between variables were assessed using Spearman analysis.
𝑃 values of <0.05 were considered significant. Multivariate
binary logistic regression was used to determine associations
between patient characteristics and plasma biomarker values
and, in particular, to assess independence of effects. Patient
characteristics and assay values were, generally, parametric in
distribution; those that were not were log
10
transformed. As
outcome is binary but duration of level 3 care is a continuous
variable, duration of care was divided into quartiles and
expressed as level 3 care > median (19.8 h). Data were
expressed as odds ratio with 95% confidence interval. Excel
2007 (Microsoft, CA), Prism v5.04 (Graphpad software, CA),
and SPSS v17.0 (IBM, CA) were used for analyses. Statistical
advice was obtained from the Department of Medical Statis-
tics, Royal Brompton and Harefield NHS Foundation Trust.
3. Results
3.1. Patient Characteristics. The demographics, clinical char-
acteristics, operative variables, and postoperative outcomes
of the patient population (𝑛 = 130, 62.3% men) are shown
in Table 1. In comparison to the average patient undergoing
snCPB in the UK, these patients were older and generally
underwent more complex surgery yet survival was compa-
rable to the national average [28]. Ischemic time of 85.5min
(IQR 67–108) was similar to mean aortic cross clamping time
(85–87min) reported in a recent studywith patients of similar
complexity [29]. Postoperative systemic inflammation was
confirmed by significant elevations in plasma levels of IL-8
(𝑛 = 122) 2 h after snCPB and CRP (𝑛 = 106) measured
postoperatively on day one (Table 1).Median duration of level
3 care required was 19.3 h (IQR 13.7–40.8), and hospital LOS
was 8.9 days (IQR 7.2–13.1). Overall hospital mortality was
5%.
3.2. Plasma Levels of sRAGE and S100A8/9 Increased after
snCPB. Plasma levels of sRAGE were significantly (𝑃 <
0.0001, 𝑛 = 129) higher in patients 2 h after snCPB
(1.93 ng/mL, IQR 1.14–2.63) compared with levels in paired
samples taken prior to surgery (1.06 ng/mL, IQR 0.72–1.76;
Figure 1). Plasma levels of S100A8/9 were significantly (𝑃 <
0.0001, 𝑛 = 130) higher in patients 2 h after snCPB
(2.37 𝜇g/mL, IQR 1.81–3.05) compared with those in paired
samples taken prior to surgery (0.41𝜇g/mL, IQR 0.20–0.65;
Figure 2).
No significant correlations were found between post-
operative levels of sRAGE and the patient characteristics,
operative variables, or post-operative outcomes shown in
Table 1, including PFR (𝑟 = −0.07, 𝑃 = 0.4) or duration
of ventilation (𝑟 = 0.19, 𝑃 = 0.03). No difference
was shown between sRAGE levels in those with PFR <
200mmHg and those with >200mmHg (defining cutoff for
acute lung injury (ALI)). Moreover, there were no significant
correlations between postoperative levels of S100A8/A9 with
patient characteristics, operative variables, or postoperative
outcomes except duration of CPB (𝑟 = 0.32, 𝑃 < 0.0002).
3.3. Preoperative sRAGE Level Is an Independent Determinant
of Outcome. Whilst there were no associations between
preoperative levels of S100A8/A9 and patient characteristics,
operative variables, or postoperative outcomes shown in
Table 1, significant positive associations were found between
preoperative sRAGE levels with duration of level 3 care (𝑟 =
0.30, 𝑃 = 0.0007) and hospital LOS (𝑟 = 0.31, 𝑃 = 0.0005).
Thus, duration of level 3 care was dichotomised into less
and greater than median care, and binary logistic regression
analysis was applied. Variables with statistically significant
relationships to greater than median duration (19.25 h) were
ischemic time, CPB time, log preop and postop sRAGE, and
log postop S100A8/A9 (Table 2). Of these, the only variable
with an independent relationship followingmultivariate anal-
ysis was log preop sRAGE (odds ratio 16.6, 𝑃 = 0.014;
Table 2). When a similar approach was applied to hospital
LOS, greater than median stay was significantly associated
with similar variables and also age. On multivariate analysis
preop Log sRAGE and age remained statistically significant
with preop sRAGE being the strongest predictor, statistically,
of prolonged duration of hospital LOS (Table 3).
4. Discussion
This study has shown that plasma levels of sRAGE and
S100A8/9 were raised postoperatively in patients after snCPB.
However, increased levels did not correlate with patient char-
acteristics, operative variables, or postoperative outcomes
with the exception of an association between S100A8/A9
and duration of CPB. By contrast, preoperative sRAGE levels
correlated, significantly, with prolonged duration of level 3
and hospital care. Moreover, preoperative sRAGE was the
only variable, when duration was categorised as greater
or less than the median, with an independent relationship
to duration of level care 3 and, statistically, the strongest
predictor of hospital LOS. These novel findings suggest that
higher preoperative plasma sRAGE levels are indicative of
longer recovery after cardiac surgery requiring CPB, sug-
gesting increased RAGE activation prior to surgery is not
advantageous.
S100A8/A9 makes up 40% of the cytosolic protein in
neutrophils, is released either through nonclassical secretion
or through loss of membrane integrity during necrosis, and
acts as a neutrophil chemoattractant and activator [30]. Our
findings of increased levels of S100A8/A9 support previous
reports of increased expression in other acute and chronic
inflammatory conditions including sepsis and septic shock
[4, 6, 31]. In particular, our findings correspond with a pre-
vious study showing increased S100A8/9 gene expression in
circulating leukocytes following CPB [32]. That levels in our
study correlated, positively, with duration of CPB suggests
that injurious factors consequent on surgery together with
CPB, including activation of blood during exposure to the
extracorporeal circuit; relative tissue hypoperfusion, myocar-
dial, and pulmonary ischemia; and operative tissue injury
[33], trigger release of S100 proteins. A study in children
undergoing cardiac surgery requiring CPB showed another
leukocyte S100 protein, S100A12, increased postoperatively
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Table 1: The main clinical and biochemical characteristics, operative variables, and postoperative outcomes of study patientsa.
Preoperative characteristics
Age, median (IQR) years 71 (63–77)
Male, 𝑛 (%) 81 (62.3)
Body mass index, median (IQR) kg/m2 25.7 (23.5–30.0)
Creatinine 𝜇mol/L 91 (77.5–107.5)
EuroSCORE, median (IQR) 7 (4–8)
Operative variables
Operation
CABG alone, 𝑛 (%) 1 (0.8)
Valve repair/replacement, 𝑛 (%) 73 (56.2)
CABG plus valve surgery, 𝑛 (%) 56 (43.1)
Cardiopulmonary bypass duration, median (IQR) min 115.5 (92.0–141.0)
Ischaemic time, median (IQR) min 85.5 (67.0–108.0)
Postoperative outcomes
CRP postop day 1 versus preop, median (IQR) mg/L 61 (46–94) versus 2 (1–5)†
IL-8 2 h postop versus preop, median (IQR) pg/mL 47.6 (29.5–83.0) versus 3.7 (0.0–8.3)‡
PaO2 : FiO2 ratio, mean (SEM), mmHg 280.0 (8.3)
Incidence of ALI 0/130
Duration of ventilation, median (IQR) h 16.3 (11.5–21.8)
ICU length of stay, median (IQR) h 40.5 (21.7–49.9)
Level 3 care duration, median (IQR) h 19.3 (13.7–40.8)
Hospital length of stay, median (IQR) days 8.9 (7.2–13.1)
Hospital mortality, 𝑛 (%) 5 (3.85)
IQR: interquartile range; SEM: standard error of the mean; ALI: acute lung injury; CABG: coronary artery bypass grafting; and ICU: intensive care unit.
a
𝑛 = 130 patients undergoing cardiac surgery necessitating cardiopulmonary bypass.
†
𝑃 < 0.001, 𝑛 = 106. ‡𝑃 < 0.001, 𝑛 = 122. Wilcoxon matched pairs test.
Table 2: Binary logistic regression analysis of level 3 care with patient characteristics, operative variables,and postoperative outcomesa.
Level 3 care >median (19.25 h) Univariate analysis
Odds ratio (95% CI) 𝑃
Multivariate analysis
Odds ratio (95% CI) 𝑃No mean Yes mean
Age 67.6 70.3 1.0 (1.0-1.0) 0.165
Ischaemic time 83.8 95.5 1.0 (1.0-1.0) 0.034a 1.01 (1.0-1.0) 0.887
CPB time 112.4 125.7 1.0 (1.0-1.0) 0.041a 1.0 (1.0-1.0) 0.550
Log creatinine 1.96 1.98 5.9 (0.3–124) 0.249
Log BMI 1.42 1.42 1.1 (0.1–119) 0.9742
Log EuroSCORE 0.73 0.77 2.2 (0.5–10.9) 0.325
Log sRAGE preop −0.33 −0.31 8.5 (2.2–32.5) 0.002a 16.6 (1.8–155.4) 0.014b
Log sRAGE postop 0.34 0.42 3.7 (1.0–14.5) 0.065 0.24 (0.0–2.7) 0.244
Log S100A8/9 preop −0.04 0.13 1.5 (0.3–6.8) 0.617
Log S100A8/9 postop 0.20 0.29 11.7 (1.5–89.4) 0.018a 5.7 (0.6–52.1) 0.120
CPB: cardiopulmonary bypass; BMI: body mass index; and 𝑛 = 124.
aSignificant relationship following univariate analysis.
bSignificant relationship following multivariate analysis.
and levels were correlated with respiratory parameters, ICU
and hospital length of stay [22]. However, the patient group
in this study by Liu and colleagues was dissimilar to ours; not
least, because a number of children in their study developed
ALI, whereas no adult in our study group did. For this reason,
we chose not to measure markers of lung injury such as
surfactant derived proteins, in addition to sRAGE, as others
have done previously [23]. The study by Liu and colleagues
also showed that sRAGE levels in children doubled 1 h after
snCPB; which is a similar fold increase to that reported in
a pilot study in aduts undergoing snCPB [23] and also in
our current study. Whilst associations with outcome were
not reported in the previous study in adults [23], plasma
sRAGE levels in children, immediately postoperatively, were
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Table 3: Binary logistic regression analysis of hospital length of stay with patient characteristics, operative variables, and postoperative
outcomesa.
Hospital stay >median (8.94 days) Univariate analysis
Odds ratio (95% CI) 𝑃
Multivariate analysis
Odds ratio (95% CI) 𝑃No mean Yes mean
Age 66.7 71.3 1.0 (1.0-1.0) 0.016a 1.1 (1.0-1.1) 0.024b
Ischaemic time 81.3 98.2 1.0 (1.0-1.0) 0.003a 1.0 (1.0-1.1) 0.100
CPB time 110.2 128.0 1.0 (1.0-1.0) 0.007a 1.0 (1.0-1.0) 0.422
Log Creatinine 2.0 2.0 8.0 (0.4–169.3) 0.182
Log BMI 1.42 1.42 0.9 (0.0–102.1) 0.974
Log EuroSCORE 0.74 0.76 1.5 (0.3–7.3) 0.609
Log sRAGE preop −0.37 −0.27 18.3 (4.2–80.2) 0.000a 25.4 (1.3–483.6) 0.032b
Log sRAGE postop 0.36 0.40 12.1 (2.7–54.2) 0.001a 2.9 (0.1–66.5) 0.500
Log S100A8/9 preop −0.70 −0.15 4.6 (0.9–24.0) 0.068 2.4 (0.3–18.6) 0.407
Log S100A8/9 postop 0.16 0.32 3.7 (0.5–25.5) 0.181
CPB: cardiopulmonary bypass; BMI: body mass index; and 𝑛 = 124.
aSignificant relationship following univariate analysis.
bSignificant relationship following multivariate analysis.
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Figure 1: Plasma levels of sRAGE increased 2 h after surgery
necessitating cardiopulmonary bypass compared with preoperative
levels. Data presented as bar graphs withmedian and 75th percentile
concentrations of sRAGE indicated 𝑛 = 129, ∗∗∗𝑃 < 0.001.
shown to be an independent predictor of postop ALI [22].
However, it is difficult to draw comparisons between the
lack of association between sRAGE levels and outcome we
found since the patient groups are, as mentioned previously,
very different. Generally, in critically ill adult patients raised
plasma levels of sRAGE denote a worse outcome [15–18]. As
the sRAGE levels measured in these studies are either similar
or greater than the levels in the current study (1.93 ng/mL),
differences in levels alone are unlikely to explain the lack
of association of postoperative sRAGE and determinants of
outcome.
In contrast to the range of studies in which sRAGE
or RAGE ligands have been measured after inflammatory
insult, few can or have assessed preinsult levels. Another
study showed that HMGB-1, a RAGE ligand, was a preop-
erative predictor of clinical course after surgery for thoracic
oesophagectomy [34]. Thus, our findings that preoperative
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Figure 2: Plasma levels of S100A8/9 increased 2 h after surgery
necessitating cardiopulmonary bypass compared with preoperative
levels. Data presented as bar graphs withmedian and 75th percentile
concentrations of S100A8/A9 indicated 𝑛 = 130, ∗∗∗𝑃 < 0.001.
sRAGE levels are suggestive of an outcome are unique and
intriguing. It is generally accepted that sRAGE acts as a com-
petitive antagonist of cellular RAGE-mediated inflammation
[1] by binding to circulating RAGE ligands it reduces ligand
interaction with membrane-bound cellular RAGE. If sRAGE
was to possess such anti-inflammatory actions, it might be
expected to show an inverse, protective, association with
duration of critical illness following snCPB as seen in studies
of other conditions.However, an alternative hypothesis is that
sRAGE could reflect ongoing low-level inflammation either
cleaved from cells to reduce the consequences of membrane
RAGE activation or secreted as a consequence of RAGE
activation, as part of a positive feedback loop. Consistent with
the two-hit hypothesis, higher preoperative sRAGE can be
considered indicative of RAGE activation due to underlying
conditions. It is of note that our previous findings in a similar
patient cohort showed no significant difference in sRAGE
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levels with or without the following comorbidities: diabetes,
pulmonary hypertension, stage of chronic kidney disease,
and ischaemic heart disease (unpublished observation), sug-
gesting it is unlikely that any of these comorbidities, at
least alone, contributes to greater preoperative sRAGE levels.
Surgical insult/CPB constitutes a second inflammatory hit
(indicated by increased CRP and IL-8 levels in those patients
in whom sufficient plasma sample was available for assay),
which coupled with greater preoperative RAGE activation
leads to worse outcome, that is, prolonged duration of care.
A limitation to these investigations is the lack of standard-
isation of perioperative care. In common with the majority
of similar observational cohort studies there was no standard
protocol for specific management by the anaesthetist, perfu-
sionist, or cardiac surgeon and thus, this might have varied
slightly between patients. Also the anaesthetic, neuromuscu-
lar blocking agent and fluid resuscitation strategy all have the
potential tomodulate the inflammatory response and, poten-
tially, postoperative sRAGE levels. A lack of information
about all preoperative medications which might influence
sRAGE levels is also a limitation of this study. Also, level 3
care is not by any means a perfect measure of “intensive”
care but is potentially more sensitive than the length of time
that a patient is located within an intensive care unit. Finally,
focusing on a select group of patients (those at higher risk, i.e.,
with a higher EuroSCORE or who underwent more complex
surgery) could, to some extent, limit the wider applicability
of these findings. However, we chose to concentrate on this
patient group in order to investigate our hypothesis; and
having proven it, in principle, we would now propose to
undertake a larger, inclusive study in order to further validate
our findings.
In conclusion, we have shown plasma levels of sRAGE
prior to snCPB to be related to the requirement for extended
(greater than median) duration of enhanced (i.e., level 3)
critical care. No such association was shown with patient age,
severity score for operative risk (EuroSCORE), or the dura-
tion of cardiopulmonary ischaemia, factors usually associated
with morbidity and late mortality [35–37]. Preoperative
sRAGE might be a biomarker that could offer superior risk
stratification of patients undergoing major elective surgery
and is worthy of further investigation as a potential therapeu-
tic target.
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